Literature DB >> 18657869

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

Calman A Maclennan1, Angela Vincent, Alexander Marx, Nicholas Willcox, Nils Eric Gilhus, John Newsom-Davis, David Beeson.   

Abstract

The role of antigen expression by thymomas in myasthenia gravis (MG) is not clear. Previous reports of acetylcholine receptor (AChR) mRNA expression by the highly sensitive reverse transcription-polymerase chain reactions (RT-PCR) produced varying results. To try to clarify this issue, we first used RT-PCR but then turned to the more accurate and quantitative RNase protection assays (RPA) to assess AChR subunit mRNA expression in thymomas from 25 patients (22 with MG). By RT-PCR, all five AChR subunits could be detected in many thymomas. However, by RPA, the mRNA for the adult-specific AChR epsilon-subunit was found in 13/25 (52%) thymomas, but not mRNA for the other subunits. AChR epsilon-subunit was more frequently detected in thymomas of A or AB histology (WHO classification) than those with B1-B3 histology. Overall, 6/6 with thymomas of A or AB histology were positive compared with only 8/19 with B histology (p=0.02). Autoantibodies in the two patients with the highest levels of epsilon-subunit mRNA bound better to adult (alpha(2)betadeltaepsilon) AChR than to fetal (alpha(2)betadeltagamma) AChR, whereas the other sera bound better to fetal AChR. The greater abundance of mRNA for AChR epsilon-subunit than for other subunits suggests that the AChR epsilon-subunit may play a distinctive role in autosensitization in MG-associated thymomas, particularly those of type A or AB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657869     DOI: 10.1016/j.jneuroim.2008.06.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.

Authors:  Peter K Gregersen; Roman Kosoy; Annette T Lee; Janine Lamb; Jon Sussman; David McKee; Kim R Simpfendorfer; Ritva Pirskanen-Matell; Frederik Piehl; Qiang Pan-Hammarstrom; Jan J G M Verschuuren; Maarten J Titulaer; Erik H Niks; Alexander Marx; Philipp Ströbel; Björn Tackenberg; Michael Pütz; Angelina Maniaol; Ahmed Elsais; Chantal Tallaksen; Hanne F Harbo; Benedicte A Lie; Soumya Raychaudhuri; Paul I W de Bakker; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Lennart Hammarstrom; Michael F Seldin
Journal:  Ann Neurol       Date:  2012-10-10       Impact factor: 10.422

2.  Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.

Authors:  Anette S B Wolff; Jaanika Kärner; Jone F Owe; Bergithe E V Oftedal; Nils Erik Gilhus; Martina M Erichsen; Olle Kämpe; Anthony Meager; Pärt Peterson; Kai Kisand; Nick Willcox; Eystein S Husebye
Journal:  J Immunol       Date:  2014-09-17       Impact factor: 5.422

3.  A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.

Authors:  Hironori Bando; Genzo Iguchi; Yasuhiko Okimura; Yukiko Odake; Kenichi Yoshida; Ryusaku Matsumoto; Kentaro Suda; Hitoshi Nishizawa; Hidenori Fukuoka; Atsuko Mokubo; Katsuyoshi Tojo; Yoshimasa Maniwa; Wataru Ogawa; Yutaka Takahashi
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

Review 4.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

5.  Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.

Authors:  Yosuke Yamada; Cleo-Aron Weis; Julian Thelen; Carsten Sticht; Berthold Schalke; Philipp Ströbel; Alexander Marx
Journal:  Front Immunol       Date:  2020-04-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.